EUVIMEDOpdag EUVIMED
Crossref

Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series

Richard Han iD, William R Spratt, Howard Yang, Francis Y X Lai, Senhong Lee

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf246 ↗

At a glance

Journal article in Clinical and Experimental Dermatology, 2025. Written by Richard Han and 4 co-authors. Institution: Department of Dermatology, Monash Health, Melbourne, VIC, Australia. Major MEDLINE topics: Pityriasis Rubra Pilaris, Dermatologic Agents, Biological Products. Cited 2 times so far (Crossref); 10 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis. There are limited data on its treatment with biologic therapies. We present a case series to evaluate the efficacy, time to primary response (TTPR) and tolerability of biologics in PRP management. A retrospective analysis of 11 patients with PRP treated with biologics at a tertiary Australian dermatology department was conducted. Patient demographics, prior therapies and treatment outcomes were reviewed. Biologics demonstrated variable efficacy: significant responses were seen with secukinumab (three of four, 75%), tildrakizumab (two of seven, 29%), ixekizumab (one of two, 50%) and risankizumab (one of one, 100%). Adalimumab yielded a partial response for two of three patients (67%). Combination therapy with systemic agents appeared to improve outcomes. Tildrakizumab had the shortest mean TTPR (6.8 weeks). Adverse effects were rare but led to treatment discontinuation in three patients. Sequential biologic therapy demonstrated some benefit to those who did not initially respond. These findings highlight the need for standardized treatment outcome measures and further research in PRP treatment.

Subjects

MeSH terms (MEDLINE)

Pityriasis Rubra PilarisDermatologic AgentsBiological ProductsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedAntibodies, Monoclonal, HumanizedTreatment OutcomeAdalimumabAntibodies, MonoclonalAgedYoung Adult

Substances

Antibodies, Monoclonal, HumanizedDermatologic AgentsixekizumabAdalimumabsecukinumabtildrakizumabAntibodies, MonoclonalBiological Products

Authors and institutions

  • Department of Dermatology, Monash Health, Melbourne, VIC, Australia.
  • Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
  • Skin Health Institute, Melbourne, VIC, Australia.

ORCID profiles: Richard Han

Cite

APA

Han, R., Spratt, W. R., Yang, H., Lai, F. Y. X., & Lee, S. (2025). Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf246

Vancouver

Han R, Spratt WR, Yang H, Lai FYX, Lee S. Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf246

BibTeX
@article{Han2025,
  author = {Han, Richard and Spratt, William R and Yang, Howard and Lai, Francis Y X and Lee, Senhong},
  title = {Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf246}
}
Start for free →